1. Therapy with Efavirenz plus Indinavir in Patients with Extensive Prior Nucleoside Reverse‐Transcriptase Inhibitor Experience: A Randomized, Double‐Blind, Placebo‐Controlled Trial
- Author
-
W. Jeffrey Fessel, Lynn M. Ploughman, Douglas J. Manion, David W. Haas, Dominic F. Labriola, Mark H. Kaplan, Robert Delapenha, Harold A. Kessler, Nancy Ruiz, and Daniel Seekins
- Subjects
Adult ,Cyclopropanes ,Male ,medicine.medical_specialty ,Efavirenz ,Anti-HIV Agents ,Placebo-controlled study ,HIV Infections ,Indinavir ,Biology ,Placebo ,Gastroenterology ,Nucleoside Reverse Transcriptase Inhibitor ,chemistry.chemical_compound ,Double-Blind Method ,immune system diseases ,Internal medicine ,Oxazines ,medicine ,Humans ,Immunology and Allergy ,Reverse-transcriptase inhibitor ,Nucleoside analogue ,virus diseases ,Middle Aged ,biochemical phenomena, metabolism, and nutrition ,Virology ,Benzoxazines ,CD4 Lymphocyte Count ,Treatment Outcome ,Infectious Diseases ,chemistry ,Alkynes ,Concomitant ,HIV-1 ,RNA, Viral ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,medicine.drug - Abstract
A randomized, double-blind, placebo-controlled trial compared efavirenz (600 mg every 24 h) plus indinavir (1000 mg every 8 h) with placebo (every 24 h) plus indinavir (800 mg every 8 h) among 327 nucleoside analogue reverse-transcriptase inhibitor (NRTI)—experienced human immunodeficiency virus (HIV)—infected adults. Patients received ⩽2 concomitant NRTIs. Eligible patients had CD4 cell counts >50 cells/mm 3 , >10,000 plasma HIV-1 RNA copies/mL, and no prior protease inhibitor or non-NRTI therapy. Patients had a mean of 2.8 years of prior NRTI therapy. At 24 weeks, plasma HIV-1 RNA level was
- Published
- 2001
- Full Text
- View/download PDF